Merck & Co. (MRK) reported its quarterly results on Friday. The pharma major posted earnings and revenue that beat estimates. MRK posted an unexpected increase in its second-quarter revenue. MRK has struggled since 2010 as its revenue has come under pressure due to patents on key products expiring. While this problem was faced by other major pharma companies as well, many of them have recovered. MRK, on the other hand, has been a bit slow with its recovery. But second-quarter results indicate that it is now on the recovery path. That doesn’t mean that challenges won’t continue. According to Credit Suisse analyst Vamil Divan, the company will face sales declines in the next few years for top drugs such as Vytorin and Zetia as generics enter the market. Still I believe that MRK is an attractive opportunity for income investors, with a yield of more than 3%.